Summit Trail Advisors’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$912K Sell
16,756
-98
-0.6% -$4.77K 0.01% 1022
2026
Q1
$723K Buy
16,854
+193
+1% +$8.3K 0.01% 1044
2025
Q4
$730K Sell
16,661
-367
-2% -$15.2K 0.01% 965
2025
Q3
$703K Buy
17,028
+497
+3% +$20K 0.01% 980
2025
Q2
$729K Buy
16,531
+8,509
+106% +$340K 0.01% 584
2025
Q1
$296K Buy
8,022
+1,112
+16% +$39.6K 0.01% 330
2024
Q4
$230K Buy
+6,910
New +$224K 0.01% 333
2018
Q1
Sell
-337
Closed -$10K 829
2017
Q4
$10K Buy
+337
New +$8.96K ﹤0.01% 1222

Other funds holding EXEL

Summit Trail Advisors's EXEL Position: Q2 2026 in Review

Summit Trail Advisors reduced its Exelixis (EXEL) stake by 0.58% in Q2 2026, selling an estimated $4.77K and leaving 16,756 shares worth $912K. The position accounts for 0.01% of the portfolio, ranked #1022.

Summit Trail Advisors first reported a position in EXEL in Q4 2017 and has held it in 8 quarters since. 758 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • Summit Trail Advisors held 16,756 shares of Exelixis worth $912K as of Q2 2026.
  • Summit Trail Advisors sold 98 Exelixis shares in Q2 2026, an estimated $4.77K.
  • Exelixis made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1022 holding.
  • Summit Trail Advisors first reported a position in Exelixis in Q4 2017 and has held it in 8 quarters since.
  • 758 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.